Rezolute, Inc.
US ˙ NasdaqCM ˙ US76200L3096

Introduction

This page provides a comprehensive analysis of the known insider trading history of Nerissa Kreher. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Nerissa Kreher has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RZLT / Rezolute, Inc. Director 37,576
US:TRDA / Entrada Therapeutics, Inc. Chief Medical Officer 40,037
US:AVRO / AVROBIO, Inc. Chief Medical Officer 24,629
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Nerissa Kreher. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases RZLT / Rezolute, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in RZLT / Rezolute, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2025-06-13 RZLT KREHER NERISSA 3,076 3.2500 3,076 3.2500 9,997 89 8.1000 14,919 149.23

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RZLT / Rezolute, Inc. Insider Trades
Insider Sales RZLT / Rezolute, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in RZLT / Rezolute, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RZLT / Rezolute, Inc. Insider Trades
Insider Purchases TRDA / Entrada Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in RZLT / Rezolute, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRDA / Entrada Therapeutics, Inc. Insider Trades
Insider Sales TRDA / Entrada Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in RZLT / Rezolute, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRDA / Entrada Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Nerissa Kreher as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-23 2025-06-13 4 RZLT Rezolute, Inc.
Common Shares
P - Purchase 3,076 37,576 8.92 3.25 9,997 122,122
2025-06-13 2025-06-10 4 RZLT Rezolute, Inc.
Common Shares
A - Award 9,000 34,500 35.29
2025-02-19 2025-02-16 4 RZLT Rezolute, Inc.
Common Shares
A - Award 25,500 25,500
2023-09-06 2023-09-06 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -21 40,037 -0.05 14.00 -294 560,518
2023-09-06 2023-09-06 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -871 40,058 -2.13 13.46 -11,728 539,369
2023-09-06 2023-09-05 4 TRDA Entrada Therapeutics, Inc.
Common Stock
F - Taxes -401 40,929 -0.97 14.46 -5,799 591,936
2023-09-06 2023-09-01 4 TRDA Entrada Therapeutics, Inc.
Common Stock
A - Award 14,200 41,330 52.34
2023-08-04 2023-08-04 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -6,898 27,130 -20.27 14.14 -97,521 383,553
2023-08-04 2023-08-04 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 6,898 34,028 25.43 2.10 14,486 71,459
2023-08-04 2023-08-03 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -9,464 27,130 -25.86 14.74 -139,530 399,983
2023-08-04 2023-08-03 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 9,464 36,594 34.88 2.10 19,874 76,847
2023-08-04 2023-08-02 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -68 27,130 -0.25 16.82 -1,144 456,327
2023-08-04 2023-08-02 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -1,000 27,198 -3.55 16.01 -16,012 435,486
2023-08-04 2023-08-02 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -9,280 28,198 -24.76 15.09 -140,013 425,440
2023-08-04 2023-08-02 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 10,348 37,478 38.14 2.10 21,731 78,704
2023-04-19 2023-03-01 4/A TRDA Entrada Therapeutics, Inc.
Common Stock
A - Award 14,200 27,130 109.82
2023-03-03 2023-03-02 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -164 41,330 -0.40 11.22 -1,841 463,834
2023-03-03 2023-03-02 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -1,477 41,494 -3.44 10.49 -15,496 435,322
2023-03-03 2023-03-02 4 TRDA Entrada Therapeutics, Inc.
Common Stock
F - Taxes -945 42,971 -2.15 11.60 -10,958 498,300
2023-03-03 2023-03-01 4 TRDA Entrada Therapeutics, Inc.
Common Stock
A - Award 28,400 43,916 183.04
2023-01-03 2022-12-30 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -5,200 15,516 -25.10 13.45 -69,932 208,665
2022-10-27 2022-10-26 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -4,317 20,716 -17.25 22.01 -95,021 455,976
2022-10-27 2022-10-26 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -643 25,033 -2.50 21.21 -13,638 530,960
2022-10-27 2022-10-26 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 4,960 25,676 23.94 2.10 10,416 53,920
2022-10-27 2022-10-25 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -100 20,716 -0.48 22.13 -2,213 458,445
2022-10-27 2022-10-25 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -2,998 20,816 -12.59 21.42 -64,215 445,864
2022-10-27 2022-10-25 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -4,942 23,814 -17.19 20.53 -101,462 488,913
2022-10-27 2022-10-25 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 8,040 28,756 38.81 2.10 16,884 60,388
2022-09-28 2022-09-28 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -3,122 20,716 -13.10 15.25 -47,610 315,913
2022-09-28 2022-09-28 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 3,122 23,838 15.07 2.10 6,556 50,060
2022-09-28 2022-09-27 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -2,403 20,716 -10.39 15.31 -36,789 317,154
2022-09-28 2022-09-27 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 2,403 23,119 11.60 2.10 5,046 48,550
2022-09-28 2022-09-26 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -300 20,716 -1.43 16.33 -4,899 338,292
2022-09-28 2022-09-26 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -2,768 21,016 -11.64 15.22 -42,131 319,876
2022-09-28 2022-09-26 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 3,068 23,784 14.81 2.10 6,443 49,946
2022-09-23 2022-09-23 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -939 20,716 -4.34 15.09 -14,167 312,544
2022-09-23 2022-09-23 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 939 21,655 4.53 2.10 1,972 45,476
2022-09-23 2022-09-21 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -3,341 20,716 -13.89 15.08 -50,393 312,466
2022-09-23 2022-09-21 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 3,341 24,057 16.13 2.10 7,016 50,520
2022-09-19 2022-09-15 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -106 20,716 -0.51 15.01 -1,591 311,018
2022-09-19 2022-09-15 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 106 20,822 0.51 2.10 223 43,726
2022-09-12 2022-09-09 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -800 20,716 -3.72 15.07 -12,054 312,126
2022-09-12 2022-09-09 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 800 21,516 3.86 2.10 1,680 45,184
2022-09-12 2022-09-08 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale X -1,221 20,716 -5.57 15.13 -18,478 313,501
2022-09-12 2022-09-08 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise X 1,221 21,937 5.89 2.10 2,564 46,068
2022-09-06 2022-09-01 4 TRDA Entrada Therapeutics, Inc.
Common Stock
A - Award 5,172 20,716 33.27
2022-03-03 2022-03-01 4 TRDA Entrada Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 62,063 62,063
2022-03-03 2022-03-01 4 TRDA Entrada Therapeutics, Inc.
Common Stock
A - Award 10,344 15,544 198.92
2021-12-29 2021-12-29 4 TRDA Entrada Therapeutics, Inc.
Stock Option (Right to Buy)
X - Other -5,200 142,722 -3.52
2021-12-29 2021-12-29 4 TRDA Entrada Therapeutics, Inc.
Common Stock
M - Exercise 5,200 5,200 2.10 10,920 10,920
2021-11-01 2021-10-28 4 TRDA Entrada Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 72,012 72,012
2021-07-14 2021-06-14 4 RZLT Rezolute, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2018-10-10 2018-10-08 4 AVRO AVROBIO, Inc.
Stock Option (Right to Buy)
M - Exercise -2,942 24,629 -10.67
2018-10-10 2018-10-08 4 AVRO AVROBIO, Inc.
Common Stock
M - Exercise 2,942 2,942 0.91 2,677 2,677
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)